Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Tumor & fibroid embolization · South Carolina | Tumor & fibroid embolization · Florida | |
|---|---|---|
| Surgeons, 2024 | 7 | 29 |
| Medicare fee-for-service cases | 207 | 1,301 |
| Growth since 2019 (Medicare FFS) | −3.3%/yr | +2.9%/yr |
| Forecast cases (Medicare FFS) | 820 in 2030 | 3,590 in 2030 |
| Forecast growth | +26%/yr to 2030 | +18%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 0.3 | 0.6 |
| Medicare Advantage share | 48% | 60% |
| Out of hospital | 46% (+46 pts since 2019) | 55% (+45 pts since 2019) |
| Cases per surgeon | 30 | 45 |
| Top 10 surgeons' share | 100% | 63% |
| Surgeons growing | 0 | 3 |
| New since the base year | 0 | 6 |
| Likely to stop billing it | 3 by 2026 | 8 by 2026 |
| Forecast miss, 1 year (procedure) | 11% | 11% |
| Company payments per surgeon | $30K | $57K |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.